Searched for
ZEPBOUND
Diabetes, weight-loss drugs Novo Nordisk's Ozempic, Wegovy, Eli Lilly's Mounjaro, Zepbound pose potential threat to eye, sudden vision loss, warns US FDAEli Lilly's Mounjaro and Zepbound and Novo Nordisk's Ozempic and Wegovy were under scanner of United States Food and Drug Administration (U...- GLP-1 boom in China, India, Brazil could create $22 billion market by 2035, J.P. Morgan saysThe China-India-Brazil market for GLP-1 weight-loss drugs could expand to $22 billion by 2035 from $6.6 billion currently, J.P. Morgan esti...
- Beauty firms chase 'Ozempic face' market as weight-loss drugs boomGalderma, Natura, and L'Oreal are developing treatments for consumers experiencing facial sagging due to rapid weight loss. These companies...
- India has biotech talent and know-how, but funding ecosystem lags: Lilly CEOEli Lilly intends to innovate in the weight-loss market, launching up to four new products in the coming years. The success of Mounjaro and...
- GLP-1 users are suing over vision loss: What does the evidence really show?Dozens of patients have taken legal action against drug manufacturers, filing personal injury lawsuits that allege they were not adequately...
- Wegovy maker Novo Nordisk faces investor pressure to find growth beyond weight-loss drugsFacing increased scrutiny, Novo Nordisk must clarify its future strategy outside of its leading weight-loss drug. Investors are advocating ...
- Novo Nordisk sues Eli Lilly, accusing it of false advertising of weight-loss drugNovo Nordisk has sued Eli Lilly in a U.S. court. The Danish company accuses Lilly of false advertising for its weight-loss medicines. Novo ...
- US Stocks: Eli Lilly raises annual forecasts as GLP-1 drugs fuel growthEli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...
- LLY stock jumps 9%: Why Eli Lilly stock is soaring today - Mounjaro, Zepbound sales drive massive earnings beat and 2026 forecast stuns Wall StreetLLY stock today: Eli Lilly's stock saw a significant jump following impressive fourth-quarter results and a strong 2026 financial forecast....
- Eli Lilly cuts Zepbound price to widen access for obesity drugEli Lilly has reduced the cost of its popular obesity drug Zepbound for American patients. This move aims to make the treatment more access...
- Eli Lilly becomes first healthcare firm to hit $1 trillion market cap - here’s why LLY stock has jumped over 36% this yearEli Lilly stock today: Eli Lilly achieved a historic milestone, briefly touching a $1 trillion market cap. This success is driven by strong...
- Eli Lilly drops CVS drug plan for staff after Novo obesity deal: ReportEli Lilly is switching its employee drug benefit plan from CVS Health to Rightway, a move reportedly linked to CVS's decision to stop cover...
- Eli Lilly Q2 earnings beat expectations on Mounjaro, Zepbound sales, stock falls after obesity drug trial missLilly stock latest news: Eli Lilly's Q2 earnings soared, fueled by Mounjaro and Zepbound's impressive sales, leading to raised full-year gu...
- New data show most US patients now stay on Wegovy, Zepbound after a yearA recent analysis of U.S. pharmacy claims reveals that nearly two-thirds of patients who initiated Wegovy or Zepbound in early 2024 continu...
- This anti-diabetic drug used for weight loss has been approved by US FDA: When will India see its launch?The FDA approves Zepbound, originally used for type 2 diabetes and weight loss, for treating obstructive sleep apnea (OSA) in obese adults....
- Zepbound: The new weight loss pill that’s set to beat Wegovy, according to Eli LillyEli Lilly’s Zepbound has outperformed Novo Nordisk’s Wegovy in a recent clinical trial, with patients losing more weight on average. While ...
- Americans hungry for weight-loss drugs grapple with supply and insurance hurdlesDespite supply chain issues easing, patients seeking weight-loss drugs like Wegovy and Zepbound are turning to cheaper compounded versions ...
- Lilly lifts sales forecast by $3 billion as weight-loss drug powers resultsAnalysts have said the companies will likely split the U.S. market roughly 50-50 by the end of 2024, as Lilly bolsters its manufacturing ca...
- Eli Lilly rises 6%; company raises 2024 sales forecast by $2 billionExplosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise its annual sales...
- Lilly rides wave of weight-loss drug demand, working to expand capacityShares were off about 1% at $696.82 after gaining about 11% in January, making Lilly the eighth largest company in the U.S. by market capit...
Load More
